TY - JOUR T1 - Growth hormone treatment in small for gestational age children in Spain JO - Anales de Pediatría (English Edition) T2 - AU - Rial Rodríguez,José Manuel AU - de Arriba Muñoz,Antonio AU - Bosch Muñoz,Jordi AU - Cabanas Rodríguez,Paloma AU - Cañete Estrada,Ramón AU - Díez López,Ignacio AU - Hawkins Solís,María Magdalena AU - Martínez-Aedo Ollero,María José AU - Rodríguez Dehli,Ana Cristina AU - Ibáñez Toda,Lourdes SN - 23412879 M3 - 10.1016/j.anpede.2016.04.008 DO - 10.1016/j.anpede.2016.04.008 UR - https://analesdepediatria.org/en-growth-hormone-treatment-in-small-articulo-S2341287917300716 AB - IntroductionSince its approval by the European Medicines Agency, a great number of patients born small for gestational date have received recombinant growth hormone treatment in Spain. The aim of this study is to analyse its outcome in the setting of ordinary clinical practice. MethodsInformation was gathered from the registers of the assessment boards that authorise all growth hormone treatments prescribed in public hospitals in six autonomic communities (regions). ResultsValid data from 974 patients was obtained. All of them complied with criteria established by the European Medicines Agency. Patients in the sample were smaller in length than weight at birth, with their median target height being below 1 standard deviation (SD), and 23% of them had been delivered prematurely. Treatment was started at 7.2±2.8 years (mean±SD). The mean patient height at start was −3.1±0.8 SD. They gained 0.7±0.2 SD in the first year, and 1.2±0.8 SD after two years. Final height was attained by 8% of the sample, reaching −1.4±0.7 SD. ConclusionsThese results are similar to other Spanish and international published studies, and are representative of the current practice in Spain.Despite treatment being started at a late age, adequate growth is observed in the short term and in the final height. Up to a 24% of patients show a poor response in the first year. ER -